Abstract
The current review focuses on the diverse molecular targets modulated by curcumin that contribute to its efficacy against colon cancers. Curcumin, (diferuloylmethane) is a yellow pigment present in the spice turmeric (Curcuma longa) polyphenolic constituent, is the most active ingredient in the traditional herbal remedy. Dietary spice turmeric is obtained from the rhizome. It has been associated with over 150 potentially therapeutic activities, including antioxidant, anti-inflammatory, anticancer, antiviral, and antibacterial activities as indicated by many citations. Research has shown curcumin to be a highly pleiotropic molecule capable of interacting with numerous molecular targets involved in inflammation. Based on early cell culture and animal research, clinical trials indicates curcumin may have potential as a therapeutic agent in diseases such as inflammatory bowel disease, pancreatitis, arthritis, and chronic anterior uveitis, as well as certain types of cancer. Because of curcumin's rapid plasma clearance and conjugation, its therapeutic usefulness has been somewhat limited, leading researchers to investigate the benefits of complexing curcumin with other substances to increase systemic bioavailability. Numerous clinical trials in progresses should provide an even deeper understanding of the mechanisms and therapeutic potential of curcumin on colon cancer. As discussed in this review, various scientific reports revealed that curcumin has demonstrated powerful anti-cancer effects in a variety of malignancies via its effects on a host of biological pathways involving a number of transcription factors, growth factors, inflammatory cytokines, protein kinases, and other oncogenic molecules in tumorigenesis and cellular growth. The anticancer activities of curcumin derive from its complex chemistry as well as its ability to influence multiple signalling pathways. Curcumin has shown anti-proliferative effect in multiple cancers, and is an inhibitor of the transcription factor NF-κB and downstream gene products (cmyc, Bcl-2, COX-2, NOS, Cyclin D1, TNF-α, interleukins and MMP-9). The objective of current review is to highlight reports on use of curcumin in treatment of colon cancer and its antiinflammatory properties.